Q2 & H1 FY22 RESULT HIGHLIGHTS:
- Net Revenue at Rs 4,589.0 mn in Q2 FY22 up by 4.4% YoY
- CRAMS revenue remained flat increasing by 0.3% YoY primarily due to:
- CRAMS India revenue increased by 560.7% due to resumption of servicing of CRAMS orders after clearances received from customers
- CRAMS - Switzerland, France & China revenue decreased by 11.8% due to deferment of supply of certain commercial products already produced to the next quarter according to the customer requirements.
- Marketable Molecules revenue increased 19.9% YoY primarily due to
- Carbogen Amcis BV revenue increased by 36.3% due to increase in demand for cholesterol and Vitamin D analogues globally.
- EBITDA Margin increased to 21.6% in Q2 FY22 due to:
- CRAMS India registering significant growth in the high margin CRAMS business.
- Carbogen Amcis AG maintaining healthy margins at 20%
- Carbogen Amcis UK margins increased due to supply of higher value intermediates and starting materials.
- Net Debt excluding lease liabilities was USD 101 mn as on September 30, 2021 (USD 101 mn as on June 30, 2021).
- Capital expenditure for H1 FY22 was approximately USD 31.85 mn, which majorly includes capex at Swiss and French sites.
